Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Botensilimab by Agenus for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...
Botensilimab by Agenus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Botensilimab by Agenus for Renal Cell Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase...
Botensilimab by Agenus for Endometrial Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase III...
Botensilimab by Agenus for Metastatic Pancreatic Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Hepatocellular Carcinoma: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...
Botensilimab by Agenus for Cervical Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III...
Botensilimab by Agenus for Ovarian Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase III...
Balstilimab by Agenus for Solid Tumor: Likelihood of Approval
Balstilimab is under clinical development by Agenus and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Balstilimab by Agenus for Oropharyngeal Cancer: Likelihood of Approval
Balstilimab is under clinical development by Agenus and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
AGEN-2373 by Agenus for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
AGEN-2373 is under clinical development by Agenus and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData,...
Botensilimab by Agenus for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Botensilimab by Agenus for Metastatic Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III...
AGEN-2373 by Agenus for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
AGEN-2373 is under clinical development by Agenus and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData,...
Botensilimab by Agenus for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Botensilimab by Agenus for Metastatic Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Botensilimab by Agenus for Colorectal Cancer: Likelihood of Approval
Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III...
Zalifrelimab by Agenus for Solid Tumor: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Zalifrelimab by Agenus for Cervical Cancer: Likelihood of Approval
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...